MCL1 and B-cell non-Hodgkin lymphoma: In breast cancer, aggressive B-cell lymphoma and glioblastoma, USP9X alleviates tumor cell survival and confers chemoresistance through YAP1, XIAP or Mcl-1 stabilization [43–45].